Nippon Life India Asset Management

Robust Q2 with market share gains

AMC			Sharekhan code: NAM-INDIA			
Reco/View	Reco: Buy	\Leftrightarrow	CMP: Rs. 431	Price Target: Rs. 502	\Leftrightarrow	
	1 L	Jpgrade	↔ Maintain 🔸	Downgrade		

Summary

- Q2 numbers beat estimates with PAT growing by 47% y-o-y and ~18% q-o-q to Rs. 231 crore led by a strong rise in other income.
- Quarterly average assets under management (QAAUM) stood at Rs 2,655 billion, rising by ~33% y-o-y and ~11% q-o-q.
- Market share rose by 22 bps to 7.3% in H1FY22 driven by robust performance of funds, strong risk management and a wide distribution network.
- We maintain a Buy rating on NAM India with price target (PT) of Rs. 502.

Nippon Life India Asset Management (NAM India) recorded a robust growth of ~47% y-o-y and ~18% q-o-q in PAT to Rs 231 crore, above our estimate of Rs. 207 crore. This was primarily on account of strong increase in other income which grew by ~53% y-o-y and ~45% q-o-q. Quarterly average assets under management (QAAUM) stood at Rs 2,655 billion, an increase of ~33% y-o-y and ~11% q-o-q with its market share increasing by 22 bps to 7.3% in H1FY22. This increase was driven by good performance of funds, robust risk management and wide distribution network.

Key positives

- Market share increased by 22 bps to 7.3% in H1FY22.
- NAM India added 18 lakh investors versus 40 lakh for the industry in H1FY22.

Key negatives

B-15 cities' contribution stood at 19% in Q2FY22 versus 23% in Q1FY22.

Management Commentary

- The company expects the industry growth momentum (31% y-o-y) to continue in the next 3-5 years supported by long term confidence in the mutual funds products.
- The management sounded confident to continue to regain its market share going ahead.

Our Call

Valuation – We believe that NAM India is in a better position to deliver on profitability given its robust AUM growth. Additionally, overall expenses remained under control which is commendable and would contribute to its profitability. Its strategic focus on retail segment coupled by strong focus on the B-30 cities is expected to bode well for the company. We expect NAM India AAUM to clock ~14% CAGR over FY22E-FY24 E. It is also likely to benefit from leveraging Nippon Life's network to garner offshore mandates which would be a key to its future growth. Further, a sustained flow into MF and equity market coupled with its widening distribution network is expected to retain its growth momentum. Hence, we maintain our Buy rating on NAM India with price target (PT) of Rs. 502..

Key Risks

Any prolonged weakness in benchmark stock indices can affect inflows and AUMs. Any adverse regulations on trail commissions could hamper equity inflows through mutual fund distributors and hence hinder AUM growth.

Valuation (Consolidated)						
Particulars	FY21	FY22E	FY23E	FY24E		
Total Revenue	1,419	1,517	1,762	2,006		
EBITDA Margin (%)	64.4	63.4	64.5	65.8		
PBT	877	925	1,099	1,280		
PAT	679	692	822	958		
EPS (Rs)	11.0	11.2	13.3	15.5		
RoE (%)	23.9	21.6	23.7	25.1		
P/E (x)	39.1	38.4	32.3	27.7		
Р/В (х)	8.6	8.1	7.3	6.6		

Source: Company; Sharekhan estimates

3R MATRIX

Sharekhan



Powered by the Sharekhan 3R Research Philosophy

What has changed in 3R MATRIX

	Old		New
RS		\Leftrightarrow	
RQ		\Leftrightarrow	
RV		\Leftrightarrow	


ESG I	NEW					
ESG R	23.11					
Medium Risk						
NEGL	LOW	MED	HIGH	SEVERE		
0-10 10-20 20-30 30-40						
Source: Morningstar						

Company details

Market cap:	Rs. 26,798 cr
52-week high/low:	Rs. 267 / 476
NSE volume: (No of shares)	9.9 lakh
BSE code:	540767
NSE code:	NAM-INDIA
Free float: (No of shares)	16.2 cr

Shareholding (%)

Promoters	74.0
FII	6.6
DII	8.8
Others	10.6



Price performance

(%)	1m	3m	6m	12m			
Absolute	-1.4	10.6	25.8	58.6			
Relative to Sensex	-3.5	-6.1	-2.4	7.8			
Sharekhan Research, Bloomberg							

Stock Update

Key result highlights

- Overall performance: NAM India recorded a robust growth of ~47% y-o-y and ~18% q-o-q in PAT to Rs 231 crore, above our estimate of Rs 207 crore. This was largely was primarily on account of strong increase in the other income which grew by ~53% y-o-y and ~45% q-o-q. Its quarterly average assets under management (QAAUM) stood at Rs 2,655 billion, an increase of ~33% y-o-y and ~11% q-o-q with its market share increasing by 22 bps to 7.3% in H1FY22. This increase was driven by good performance of funds, robust risk management and wide distribution network.
- **Other income:** Other income came in at Rs. 97 crore vs. our expectation of Rs. 73 crore, was up by ~53% y-o-y and ~45% q-o-q. This was led by MTM gains, which the management believes would be range bound going ahead.
- **Expenses:** Operating expenses exhibited stayed resilient with operating expenses as a percentage of AUM at 5 bps versus 6 bps in Q2FY21.
- **Industry:** Industry AAUM continued to grow strong and stood at Rs 36,194 billion, up by 31% y-o-y and 20% q-o-q in Q2FY22 driven by increase in the all assets classes. The company expects this momentum to continue in the next three to five years supported by long-term confidence in the mutual funds products. The management seemed to be ready for the long term opportunities going ahead and was confident to regain market share, while maintaining sustainable margins.
- AAUM: Equity funds which contributed to 43% of the AAUM grew by ~16% q-o-q. The share of debt, liquid and ETFs was 29%, 12% and 17% respectively. It continued to focus on retail assets with retail AAUM growing by ~50% y-o-y and ~34% q-o-q to Rs. 777 billion supported by strong brand recall and wide distribution network. NAM India has ~80,000 plus distributors with MFDs share at 57% to the AUM. The company plans to review its existing branch network and future expansion plan given cost effective digital channels.
- **NFOs:** With a focus on providing innovative products, the company is expected to launch several products in future. It has received approval from SEBI for mutual fund in collaboration with Cathy SITE to launch Nippon India Taiwan Equity Fund. Apart from this, it has received approval of Nippon India S&P EV Index Fund and Nippon India Nifty Auto ETF funds. In total the company has filed approvals for 8 NFOs.
- **Focus B-30 cities:** B-30 cities contributed 19% to the total AUM vs industry contribution of 31% in Q2FY22. Top 5 cities' contribution was 67% vs.56% for the industry. As of September 2021, 68% of the individual assets have a vintage of more than 12 months.
- **Others:** Its offshore business AUM comprising of advisory and managed assets was at Rs117 billion in 2QFY22 and the company intends to leverage its global partner, Nippon Life to continue to expand its international presence. The company has raised Rs 40 billion commitments in Sep'21 in category-II and category-III AIFs across assets.

Sharekhan

Results (consolidated)

Results (consolidated)	Results (consolidated)						
Particulars	2QFY22	2QFY21	1QFY22	y-o-y (%)	q-o-q (%)		
AAUM (Rs cr)	2,65,500	2,00,030	2,40,364	32.7	10.5		
Core Revenue	328	259	302	26.8	8.5		
Other Income	97	64	67	52.6	45.3		
Revenue Yield (%)	0.64	0.64	0.61	-0.42	2.6		
Operating Cost (% of AAUM)	0.05	0.06	0.05	-1.0	-0.1		
PBT	283	191	236	48.1	19.8		
Тах	70	46	55	52.2	27.4		
APAT	213	145	181	46.8	17.5		
EBITDA (%)	68.3	62.1	66.2	628.8	217.5		
NPM	50.2	45.1	49.1	510.1	102.2		
Tax rate (%)	24.6	23.9	23.2	66.7	146.1		

Source: Company; Sharekhan Research

						Rs cr
Particulars	1QFY21	2QFY21	3QFY21	4QFY21	1QFY22	2QFY22
QAAUM (Rs bn)	1,801	2,000	2,130	2,286	2,404	2,655
Equity	684	780	831	937	986	1,142
Debt	522	600	682	709	721	770
Liquid	342	340	298	274	288	319
ETFs	252	280	320	366	409	451

(%)	1QFY21	2QFY21	3QFY21	4QFY21	1QFY22	2QFY22
Equity	38	39	39	41	41	43
Debt	29	30	32	31	30	29
Liquid	19	17	14	12	12	12
ETFs	14	14	15	16	17	17

Growth (%)(q-o-q)	1QFY21	2QFY21	3QFY21	4QFY21	1QFY22	2QFY22
Equity	-20.5	14.0	6.5	12.8	5.2	15.8
Debt	-9.0	14.9	13.6	4.0	1.8	6.8
Liquid	4.4	-0.6	-12.3	-8.0	5.2	10.4
ETFs	-12.1	11.0	14.1	14.5	11.7	10.4

Growth (%)(y-o-y)	1QFY21	2QFY21	3QFY21	4QFY21	1QFY22	2QFY22
Equity	-26.8	-10.5	-7.6	8.9	44.0	46.4
Debt	-24.3	2.1	23.5	23.5	38.1	28.3
Liquid	2.5	19.9	-8.8	-16.3	-15.7	-6.3
ETFs	-5.6	-1.3	20.2	27.5	62.1	61.2

Source: Company; Sharekhan Research



Outlook and Valuation

Sector outlook – Financialisation of savings augurs well:

India's mutual fund penetration (AUM as percentage of GDP) is 10.9% in FY20, which far below the global average of 63% for the same period. However, quarterly mutual fund AAUM is expected to grow in double digits over FY21-FY25E, despite weakness in FY21. This is likely on the back of a recovery in corporate earnings, growing individual investor base led by rising household incomes, growing financial savings and robust performance in the underlying equity markets. Further, increasing awareness and supportive regulatory measures by the government would also bode well for the industry. Industry AUMs increased by 16% over March 2021 to August 2021, supported by strong inflows in equity mutual funds and record high SIP inflows of Rs. 99,200 crore in August 2021. Within this the equity funds grew by 5% m-o-m.

Company outlook – Regaining market share:

NAM India's strategy to continue its focus on the retail segment through its extensive branch infrastructure is expected to help it retain and increase its market share going ahead. Its overall market share has increased by 22 bps to 7.3% so far in Q2FY22 and seems to be stabilising after falling from highs of 9.5% in March 2019. Besides this, the company intends to focus on launching of newer and attractive products that is likely to bode well for growth. Additionally, its focus on B-30 cities aided by its strong distribution network is favorable for the company. It is well on the path of gaining business traction by leveraging Nippon Life's network in order to garner offshore mandates.

■ Valuation – Maintain Buy with a PT of Rs. 502:

We believe that NAM India is in a better position to deliver on profitability given its robust AUM growth. Additionally, overall expenses remained under control which is commendable and would contribute to its profitability. Its strategic focus on retail segment coupled by strong focus on the B-30 cities is expected to bode well for the company. We expect NAM India AAUM to clock ~14% CAGR over FY22E-FY24 E. It is also likely to benefit from leveraging Nippon Life's network to garner offshore mandates which would be a key to its future growth. Further, a sustained flow into MF and equity market coupled with its widening distribution network is expected to retain its growth momentum. Hence, we maintain our Buy rating on NAM India with price target (PT) of Rs. 502.

i cei companson									
Particulars	СМР	P/BV(x)		P/E(x)		RoA (%)		RoE (%)	
	Rs/Share	FY22E	FY23E	FY22E	FY23E	FY22E	FY23E	FY22E	FY23E
NAM India	431	8.1	7.3	38.4	32.3	19.7	21.6	21.6	23.7
HDFC AMC	2,736	11.6	9.7	39.9	34.6	28.1	28.6	30.0	30.5

Peer Comparison

Source: Company, Sharekhan research

Stock Update

About company

Nippon Life India Asset Management Ltd (NAM) – formerly known as Reliance Nippon Life Asset Management – is the asset manager for Nippon India Mutual Fund (NIMF). NAM is of the largest asset managers with 26 years of track record, advising assets across MFs, managed accounts, pension funds and offshore strategies. In addition to this, NAM also renders advisory services to its offshore clients and an approval to manage and / or advise pooled assets including offshore funds, Insurance funds, provident funds is in place. Nippon Life Insurance Company is the promoter of NAM and currently holds 74.5% of its total issued and paid-up equity share capital.

Investment theme

With a strong foothold in the B-30 cities and a wide distribution network, the company is expected to regain market share. Currently, AUM contribution from B-30 cities is at 19% as of Q1FY22, as compared to industry contribution of 16.3%. NAM India was able to witness strong traction in AAUM growth at a CAGR of 21% over FY13-18, backed by a strong distribution network, despite of being a non-bank promoted entity. Going ahead, we expect its AAUM to AAUM to clock ~14% CAGR over FY22E-FY24 E. Further, the company plans to increase its yields from the ETF segment through differentiated products and higher liquidity.

Key Risks

Any prolonged weakness in benchmark stock market indices can affect inflows and AUMs. Any adverse regulations on trail commissions could hamper equity inflows through mutual fund distributors and hence hinder AUM growth.

Additional Data

Key management personnel

Mr. Sundeep Sikka	Executive Director & Chief Executive Officer
Mr. Prateek Jain	Chief Financial Officer
Mr. Manish Gunwani	CIO - Equity Investments
Mr. Amit Tripathi	CIO - Fixed Income Investments
Source: Company Website	

Top 10 shareholders

Sr. No.	Holder Name	Holding (%)
1	Life Insurance Corp of India	3.6
2	INDUSIND BANK LTD	3.6
3	Baron Capital Inc	2.1
4	HDFC Asset Management Co Ltd	1.6
5	Vanguard Group Inc/The	0.8
6	Reliance Capital Ltd	0.8
7	Grandeur Peak Global Advisors LLC	0.5
8	Valiant Mauritius Partners Ltd	1.1
9	Blackrock	0.3
10	UTI Asset Management Co Ltd	0.3
Sourco	Pleambarg: data as an San 17 2021	

Source: Bloomberg; data as on Sep 17, 2021

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

Understanding the Sharekhan 3R Matrix

Right Sector	
Positive	Strong industry fundamentals (favorable demand-supply scenario, consistent industry growth), increasing investments, higher entry barrier, and favorable government policies
Neutral	Stagnancy in the industry growth due to macro factors and lower incremental investments by Government/private companies
Negative	Unable to recover from low in the stable economic environment, adverse government policies affecting the business fundamentals and global challenges (currency headwinds and unfavorable policies implemented by global industrial institutions) and any significant increase in commodity prices affecting profitability.
Right Quality	
Positive	Sector leader, Strong management bandwidth, Strong financial track-record, Healthy Balance sheet/cash flows, differentiated product/service portfolio and Good corporate governance.
Neutral	Macro slowdown affecting near term growth profile, Untoward events such as natural calamities resulting in near term uncertainty, Company specific events such as factory shutdown, lack of positive triggers/events in near term, raw material price movement turning unfavourable
Negative	Weakening growth trend led by led by external/internal factors, reshuffling of key management personal, questionable corporate governance, high commodity prices/weak realisation environment resulting in margin pressure and detoriating balance sheet
Right Valuation	
Positive	Strong earnings growth expectation and improving return ratios but valuations are trading at discount to industry leaders/historical average multiples, Expansion in valuation multiple due to expected outperformance amongst its peers and Industry up-cycle with conducive business environment.
Neutral	Trading at par to historical valuations and having limited scope of expansion in valuation multiples.
Negative	Trading at premium valuations but earnings outlook are weak; Emergence of roadblocks such as corporate governance issue, adverse government policies and bleak global macro environment etc warranting for lower than historical valuation multiple.

Source: Sharekhan Research

Sharekhan

by BNP PARIBAS

Know more about our products and services

For Private Circulation only

Disclaimer: This document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This Document is subject to changes without prior notice. This document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusions from the information presented in this report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst has not dealt or traded directly or indirectly in securities of the company and that all of the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst and SHAREKHAN further certifies that neither he or his relatives or Sharekhan associates has any direct or indirect financial interest nor have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report nor have any material conflict of interest nor has served as officer, director or employee or engaged in market making activity of the company and no part of the analyst has also not been a part of the team which has managed or co-managed the public offerings of the company and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Limited or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either, SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Compliance Officer: Mr. Joby John Meledan; Tel: 022-61150000; email id: compliance@sharekhan.com;

For any queries or grievances kindly email igc@sharekhan.com or contact: myaccount@sharekhan.com

Registered Office: Sharekhan Limited, 10th Floor, Beta Building, Lodha iThink Techno Campus, Off. JVLR, Opp. Kanjurmarg Railway Station, Kanjurmarg (East), Mumbai – 400042, Maharashtra. Tel: 022 - 61150000. Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O / CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669; Research Analyst: INH000006183;

Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com; Investment in securities market are subject to market risks, read all the related documents carefully before investing.

Sharekhan Research Coverage/Universe

Automobiles

Alicon Castalloy Limited Apollo Tyres Ashok Leyland Amara Raja Batteries Limited Bajaj Auto Balkrishna Industries Bosch Limited Exide Industries Limited Gabriel India Limited **GNA** Axles Limited Greaves Cotton Hero MotoCorp Lumax Auto Technologies Limited M&M Maruti Suzuki Mayur Uniquoters Ramkrishna Forgings Limited Schaeffler India Limited Sundram Fasteners Suprajit Engineering Limited Tata Motors Limited TVS Motor

Banks & Finance

AU Small Finance Bank Axis Bank Bajaj Finance Bajaj Finserv Bank of Baroda Bank of India Capital First Cholamandalam Investment and Finance Company City Union Bank Federal Bank Housing Development Finance Corporation HDFC Bank HDFC Life Insurance **ICICI Bank** ICICI Lombard General Insurance ICICI Prudential Life Insurance Company Ltd IndusInd Bank Kotak Mahindra Bank LIC Housing Finance L&T Finance Holding Max Financial Services Mahindra & Mahindra Financial Services Nippon Life India Asset Management Limited Punjab National Bank RBL Bank Repco Home Finance Limited SBI Union Bank of India

Consumer goods

Asian Paints Limited Britannia Colgate Palmolive (India) Dabur India Limited Emami **GSK** Consumers Godrej Consumer Products Hindustan Unilever Limited Indigo Paints Ltd ITC Jyothy Laboratories Limited Marico Nestle India Limited Radico Khaitan Ltd Tata Consumer Products Ltd Zydus Wellness

IT / IT services

Birlasoft Limited HCL Technologies Infosys Intellect Design Arena Limited Larsen & Toubro Infotech L&T Technology Services Mastek Limited Persistent Systems Tata Consultancy Services Tata Elxsi Limited Tech Mahindra Wipro

Capital goods / Power

Amber Enterprises Limited Blue Star Limited Carborundum Universal Limited CESC Cummins India Dixon Technologies Limited Finolex Cables Honeywell Automation India Limited Kalpataru Power Transmission Polycab India Limited Power Grid Corporation of India Limited NTPC Limited **KEC** International **KEI** Industries Tata Power Company Ltd Thermax Triveni Turbine V-Guard Industries Va Tech Wabag Ltd.

Infrastructure / Real estate

Ashoka Buildcon Limited JMC Projects (India) Limited Larsen & Toubro Mahindra Lifespace Developers Limited KNR Constructions Limited PNC Infratech Limited Sadbhav Engineering

Oil & gas

Bharat Petroleum Corporation Limited Castrol India Limited GAIL (India) Limited Gujarat Gas Ltd. Gujarat State Petronet Limited Hindustan Petroleum Corporation Limited Indraprastha Gas Limited Indian Oil Corporation Ltd Mahanagar Gas Oil India Petronet LNG Reliance Industries

Pharmaceuticals

Abbott India Limited Aurobindo Pharma Biocon Cipla Cadila Healthcare Divi's Labs Dr Reddy's Laboratories Limited Gland Pharma Limited Granules India Limited Ipca Laboratories Limited Laurus Labs Limited Lupin Sanofi India Solara Active Pharma Sciences Strides Pharma Sciences Sun Pharmaceutical Industries Torrent Pharmaceuticals

Building materials

Astral Poly Technik Limited APL Apollo Tubes Limited Dalmia Bharat Limited Grasim Industries Greenlam Industries Limited Greenpanel Industries Limited JK Lakshmi Cement Limited Kajaria Ceramics Limited Pidilite Industries Limited The Ramco Cements Shree Cement UltraTech Cement

Discretionary consumption

Aditya Birla Fashion and Retail Limited Arvind Ltd. Bata India Limited Century Plyboards (India) Inox Leisure Indian Hotels Company Limited Info Edge (India) Jubilant FoodWorks Limited PVR Ltd Relaxo Footwear Titan Company Trent Limited Welspun India Limited Wonderla Holidays Zee Entertainment Enterprises Limited

Diversified / Miscellaneous

Aarti Industries Limited Affle (India) Limited Atul Limited Bajaj Holdings & Investment Bharti Airtel **Bharat Electronics** Coromandel International Limited Coal India Limited Gateway Distriparks Insecticides (India) Limited JSW Steel Limited Mahindra Logistics Limited MOIL Limited NMDC Limited PI Industries Polyplex Corporation Limited Quess Corp Limited Ratnamani Metals and Tubes Steel Authority of India Ltd SRF Limited **TCI Express Limited** Transport Corporation of India Limited Triveni Engineering & Industries Limited Sudarshan Chemical Industries Sumitomo Chemical India Limited Supreme Industries UPI Vinati Organics Limited

Sharekhan

Peer Comparison

Particulars	СМР	CMP P/BV(x)		P/E(x)		RoA	(%)	RoE (%)		
	Rs/Share	FY20E	FY21E	FY20E	FY21E	FY20E	FY21E	FY20E	FY21E	
Х	х	Х	Х	Х	Х	Х	Х	Х	Х	
Х	X	Х	Х	Х	Х	Х	Х	Х	Х	
Х	X	Х	Х	Х	Х	Х	Х	Х	Х	
Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	

Source: Company, Sharekhan research

Peer valuation

	СМР	O/S	MCAP	P/E (x)		EV/EBIDTA (x)		P/BV (x)		RoE (%)	
Particulars	(Rs / Share)	Shares (Cr)	(Rs Cr)	FY20E	FY21E	FY20E	FY21E	FY20E	FY21E	FY20E	FY21E
Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
Х	х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
Х	х	Х	Х	Х	Х	х	Х	Х	Х	Х	Х

Source: Company, Sharekhan estimates

Peer Comparison

Dantioulana	P/E (x)		EV/EBITDA (x)		P/B	V (x)	RoE (%)	
Particulars	FY20E	FY21E	FY20E	FY21E	FY20E	FY21E	FY20E	FY21E
x	х	Х	Х	Х	Х	Х	Х	Х
x	х	Х	Х	Х	Х	Х	Х	Х
х	х	Х	Х	Х	Х	Х	Х	Х
х	х	Х	Х	Х	Х	Х	Х	Х
x	х	Х	Х	Х	Х	Х	Х	Х
х	х	Х	Х	Х	Х	Х	Х	Х

Source: Sharekhan Research

Peer Comparison

Dautionland		P/E (x)		E	V/EBIDTA (x)	RoCE (%)			
Particulars	FY19	FY20E	FY21E	FY19	FY20E	FY21E	FY19	FY20E	FY21E	
х	Х	Х	Х	Х	Х	Х	Х	Х	Х	
х	Х	Х	Х	Х	Х	Х	Х	Х	Х	
х	Х	Х	Х	Х	Х	Х	Х	Х	Х	
х	Х	Х	Х	Х	Х	Х	Х	Х	Х	
x	Х	Х	Х	Х	Х	Х	Х	Х	Х	
x	Х	Х	Х	Х	Х	Х	Х	Х	Х	
х	Х	Х	Х	Х	Х	Х	Х	Х	Х	

Source: Company, Sharekhan estimates

Peer Comparison

Dentionland	P/E (x)		EV/EBIDTA (x)		RoE (%)		D: E	
Particulars	FY2020E	FY2021E	FY2020E	FY2021E	FY2020E	FY2021E	FY2020E	FY2021E
х	х	Х	Х	Х	Х	Х	Х	Х
х	х	Х	Х	Х	Х	Х	Х	Х
х	х	Х	Х	Х	Х	Х	Х	Х
х	х	Х	Х	Х	Х	Х	Х	Х
х	х	Х	Х	Х	Х	Х	Х	Х
х	х	Х	Х	Х	Х	Х	Х	Х

Source: Sharekhan Research

Investor's Eye October XX, 2021

Index

Stock Update

XXXX

XXXX

Viewpoint

XXXX

XXXX

Sector Update

XXXX

XXXX

Visit us at www.sharekhan.com



For Private Circulation only